# Lecture 11: Pain 1 - Neuromuscular Blockers

## Neuromuscular Junction Physiology

### SNARE Complex
- **VAMP (v-SNARE synaptobrevin)** complexes with **t-SNARE syntaxin**
- **v-SNARE synaptotagmin** complexes with **t-SNARE SNAP-25**
- **VAMP + SNAP = SNARE** (enables vesicle fusion)

### Signal Transmission
1. Action potential arrives at motor neuron terminal
2. Ca2+ influx triggers vesicle fusion via SNARE proteins
3. **Acetylcholine (ACh)** released into synaptic cleft
4. ACh binds **nicotinic acetylcholine receptors** on muscle
5. Na+ influx → depolarization via T-tubules → Ca2+ influx via **RyR1** → muscle contraction
6. ACh terminated by **acetylcholinesterase (AChE)** in synaptic cleft

---

## Neuromuscular Blocking Agents (NMBs)

### Two Classes
1. **Depolarizing** (succinylcholine)
2. **Non-depolarizing** ("-curonium" drugs)

---

## Depolarizing NMBs

### Succinylcholine
| Property | Details |
|----------|---------|
| **Structure** | Two ACh molecules linked together |
| **Mechanism** | Binds nicotinic receptor, causes sustained depolarization |
| **Duration** | 5-10 minutes |
| **Metabolism** | Plasma pseudocholinesterases (not AChE) |

### Adverse Effects
1. **Prolonged paralysis** in patients with pseudocholinesterase deficiency
2. Myalgias
3. **Hyperkalemia** - dangerous in:
   - Renal patients
   - Burn patients
   - Immobile patients
   - Patients with neuromuscular diseases
4. **Malignant hyperthermia** (triggering agent)
5. **Fasciculations** (characteristic side effect - depolarizing NMBs ONLY)

---

## Non-Depolarizing NMBs

### Key Features
| Property | Details |
|----------|---------|
| **Naming** | "-curonium" drugs |
| **Prototype (US)** | Rocuronium |
| **Structure** | Two ACh molecules hidden by bulky ring structures |
| **Mechanism** | Competitive antagonism at nicotinic receptors |
| **Elimination** | Hepatic |

### Reversal Agents

| Agent | Mechanism | Notes |
|-------|-----------|-------|
| **Neostigmine/Pyridostigmine** | AChE inhibitors (increase ACh) | Co-administer with **glycopyrrolate** (muscarinic anticholinergic) to prevent cholinergic side effects (GI motility, salivation, bradycardia) |
| **Sugammadex** | Direct encapsulation of NMB | Rapid reversal; causes **failure of hormonal contraception for 7 days** |

---

## Toxins Affecting Neuromuscular Junction

### Botulinum Toxin (Botox)
| Property | Details |
|----------|---------|
| **Full name** | Onabotulinum toxin A |
| **Mechanism** | Cleaves SNARE proteins → prevents ACh vesicle fusion → **flaccid paralysis** |
| **Uses** | Muscle relaxant, migraine, spasticity, neuropathic pain, cosmetic |
| **Adverse effects** | Development of immunity, dysphagia, weakness |

### Tetanus Toxin (C. tetani)
| Property | Details |
|----------|---------|
| **Mechanism** | Cleaves SNARE proteins → prevents release of **inhibitory** NTs from Renshaw cells |
| **Effect** | Uninhibited motor neuron activation → muscle spasms, rigidity, autonomic instability |
| **Prevention** | Vaccination |

### Snake Venoms

| Toxin | Source | Mechanism |
|-------|--------|-----------|
| **Bungarotoxin** | Cobras | Irreversibly blocks nicotinic ACh receptor → paralysis |
| **Dendrotoxin** | Mamba snakes | Blocks voltage-gated K+ channels → increased ACh release (Ca2+ continues entering) |

---

## Central-Acting Muscle Relaxants

Act at the **spinal cord** level (different from peripheral NMBs)

| Drug | Mechanism | Side Effects |
|------|-----------|--------------|
| **Baclofen** | GABA-B agonist (K+ channel) | CNS depression, ataxia |
| **Dantrolene** | Ryanodine receptor 1 (RyR1) blocker | Hepatotoxic, weakness |
| **Tizanidine** | Alpha-2 agonist (inhibits presynaptic neurons) | Sedation, CNS effects |
| **Cyclobenzaprine** | TCA-like effect | Anticholinergic effects |

**Note**: Dantrolene is also used to treat **malignant hyperthermia**

---

## Organophosphate Toxicity (Sarin)

| Property | Details |
|----------|---------|
| **Mechanism** | **Irreversible** inhibition of acetylcholinesterase |
| **Effect** | Succinylcholine-like (cholinergic crisis) |
| **Treatment** | **Atropine** (blocks muscarinic effects) + **Pralidoxime** (regenerates cholinesterase within 5 hours) |

**Note**: Atropine does NOT counteract skeletal muscle effects (nicotinic receptors)

---

## Key Distinguishing Features

| Feature | Depolarizing NMB | Non-Depolarizing NMB |
|---------|------------------|---------------------|
| **Prototype** | Succinylcholine | Rocuronium |
| **Fasciculations** | YES | NO |
| **Reversal** | Wait for metabolism | Neostigmine or Sugammadex |
| **Duration** | Very short (5-10 min) | Longer |
